دورية أكاديمية
أعرض في EDS

Fosmanogepix: The Novel Anti-Fungal Agent's Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials.

التفاصيل البيبلوغرافية
العنوان: Fosmanogepix: The Novel Anti-Fungal Agent's Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials.
المؤلفون: Almajid A; Internal Medicine, King Fahad Specialist Hospital, Dammam, SAU., Bazroon A; Internal Medicine, King Fahad Specialist Hospital, Dammam, SAU., Al-Awami HM; Internal Medicine, King Fahad Specialist Hospital, Dammam, SAU., Albarbari H; Internal Medicine, King Fahad Specialist Hospital, Dammam, SAU., Alqahtani I; College of Medicine, Arabian Gulf University, Manama, BHR., Almutairi R; College of Medicine, University of Szeged Albert Szent-Györgyi Medical School, Szeged, HUN., Alsuwayj A; College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU., Alahmadi F; College of Medicine, Vision College, Riyadh, SAU., Aljawad J; College of Medicine, University of Szeged Albert Szent-Györgyi Medical School, Szeged, HUN., Alnimer R; College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU., Asiri N; College of Medicine, King Khalid University, Abha, SAU., Alajlani S; College of Medicine, Umm Al Qura University, Makkah, SAU., Alshelali R; Internal Medicine, King Abdullah Medical Complex, Jeddah, SAU., Aljishi Y; Internal Medicine, King Fahad Specialist Hospital, Dammam, SAU.
المصدر: Cureus [Cureus] 2024 Apr 28; Vol. 16 (4), pp. e59210. Date of Electronic Publication: 2024 Apr 28 (Print Publication: 2024).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Fosmanogepix, a prodrug of Manogepix (MGX), is a groundbreaking antifungal agent with broad-spectrum activity against yeasts, including Cryptococcus and Candida , as well as molds. It exhibits effectiveness against drug-resistant strains, such as Candida strains resistant to echinocandins and Aspergillus strains resistant to azoles. Furthermore, fosmanogepix shows activity against pathogens that typically resist other classes of drugs, such as Scedosporium , Lomentospora prolificans , and Fusarium , although its efficacy against Mucorales varies. In animal models, fosmanogepix has demonstrated notable effectiveness against disseminated infections caused by various Candida species, Coccidioides immitis , and Fusarium solani . It has also shown efficacy in pulmonary infection models involving Aspergillus fumigatus , Aspergillus flavus , Scedosporium prolificans , Scedosporium apiospermum , and Rhizopus arrhizus . Clinical trials have revealed excellent oral bioavailability (>90%), enabling a seamless transition between intravenous and oral formulations without compromising blood concentrations. Fosmanogepix exhibits favorable profiles in terms of drug interactions, tolerability, and extensive distribution in various tissues, making it an appealing choice for treating invasive fungal infections. This comprehensive review aims to examine the outcomes of published data on fosmanogepix, encompassing in vitro, in vivo, and clinical investigations.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2024, Almajid et al.)
References: Emerg Infect Dis. 2011 Oct;17(10):1855-64. (PMID: 22000355)
Lancet Infect Dis. 2016 Jan;16(1):100-112. (PMID: 26738840)
Antimicrob Agents Chemother. 2012 Feb;56(2):960-71. (PMID: 22143530)
Neuropediatrics. 1991 May;22(2):110-2. (PMID: 1857495)
Antimicrob Agents Chemother. 2023 May 17;67(5):e0141922. (PMID: 37022196)
PLoS Negl Trop Dis. 2014 Mar 27;8(3):e2667. (PMID: 24675533)
Mol Microbiol. 2003 May;48(4):1029-42. (PMID: 12753194)
J Antimicrob Chemother. 2011 Nov;66(11):2581-4. (PMID: 21873291)
Med Mycol. 2023 Nov 6;61(11):. (PMID: 37960934)
Antimicrob Agents Chemother. 2011 Oct;55(10):4652-8. (PMID: 21825291)
Z Gastroenterol. 2022 Aug;60(8):1231-1234. (PMID: 34781387)
Med Mycol. 2013 May;51(4):361-70. (PMID: 23210682)
J Glob Antimicrob Resist. 2021 Sep;26:117-127. (PMID: 34051400)
J Antimicrob Chemother. 2023 Nov 6;78(11):2645-2652. (PMID: 37681450)
Clin Infect Dis. 2013 Jun;56(12):1724-32. (PMID: 23487382)
J Antimicrob Chemother. 2023 Oct 3;78(10):2471-2480. (PMID: 37596890)
Antimicrob Agents Chemother. 2018 Jul 27;62(8):. (PMID: 29891599)
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0102822. (PMID: 36286491)
Antimicrob Agents Chemother. 2018 Sep 24;62(10):. (PMID: 30104264)
Antimicrob Agents Chemother. 2020 Feb 21;64(3):. (PMID: 31818813)
Clin Infect Dis. 2017 Jan 15;64(2):134-140. (PMID: 27988485)
Trans R Soc Trop Med Hyg. 2021 Apr 14;115(4):437-440. (PMID: 33320935)
Antimicrob Agents Chemother. 2021 Feb 17;65(3):. (PMID: 33361304)
Arch Acad Emerg Med. 2022 Jul 12;10(1):e56. (PMID: 36033988)
Antimicrob Agents Chemother. 2012 Jan;56(1):352-7. (PMID: 22083469)
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0220621. (PMID: 34930032)
Med Mycol. 2017 Jan 1;55(1):118-124. (PMID: 27562862)
Microbiol Spectr. 2022 Feb 23;10(1):e0171721. (PMID: 35196811)
Antimicrob Agents Chemother. 1997 Jul;41(7):1482-7. (PMID: 9210670)
J Clin Microbiol. 2013 Dec;51(12):4167-72. (PMID: 24108614)
Antimicrob Agents Chemother. 2020 Oct 20;64(11):. (PMID: 32839219)
Clin Microbiol Infect. 2014 Apr;20 Suppl 3:27-46. (PMID: 24548001)
Antimicrob Agents Chemother. 2019 Oct 22;63(11):. (PMID: 31427304)
Antimicrob Agents Chemother. 2018 Sep 24;62(10):. (PMID: 30012766)
Transpl Infect Dis. 2017 Oct;19(5):. (PMID: 28741738)
Antimicrob Agents Chemother. 2011 Nov;55(11):5155-8. (PMID: 21844312)
ACS Infect Dis. 2015 Jan 9;1(1):59-72. (PMID: 26878058)
Open Forum Infect Dis. 2023 May 23;10(6):ofad285. (PMID: 37305844)
Clin Microbiol Rev. 2007 Oct;20(4):695-704. (PMID: 17934079)
Bioorg Med Chem Lett. 2019 Dec 1;29(23):126713. (PMID: 31668974)
mBio. 2020 May 5;11(3):. (PMID: 32371596)
Clin Infect Dis. 2023 Sep 18;77(6):848-850. (PMID: 37220752)
Antimicrob Agents Chemother. 2019 Jan 29;63(2):. (PMID: 30455238)
J Antimicrob Chemother. 2019 May 1;74(5):1295-1299. (PMID: 30753499)
Antimicrob Agents Chemother. 2020 May 21;64(6):. (PMID: 32205345)
Antimicrob Agents Chemother. 2019 Jul 25;63(8):. (PMID: 31182527)
فهرسة مساهمة: Keywords: apx001; aspergillus; candida; clinical trials; e1210; e1211; fosmanogepix; gwt1.; manogepix
تواريخ الأحداث: Date Created: 20240529 Latest Revision: 20240530
رمز التحديث: 20240530
مُعرف محوري في PubMed: PMC11131969
DOI: 10.7759/cureus.59210
PMID: 38807795
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.59210